Drawing for IPAM

USPTO serial 97359213

IPAM

Reviewed by CopyMark Law Group

Reg. 7464893Status 700Registered
Filing date
Status date
Registration date
Aug 6, 2024
Examiner
GULIANO, ROBERT N
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with IPAM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

DENNIS S. PRAHL

DENNIS S. PRAHL LADAS & PARRY LLP1040 AVENUE OF THE AMERICASNEW YORK, NY 10018UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals for the treatment of cancer, epigenetic disease, neurodegenerative disease, genetic disorder, neuromuscular disease, alzheimer's disease, parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, muscle disorder, or immune related disorder; Reagents for use in medical genetic testing; Preparations for detecting mutation in prion genes for medical purposes; Diagnostic preparations for medical purposes for detecting presence of mutation in prion genes; medicines for human purposes for the treatment of cancer, epigenetic disease, neurodegenerative disease, genetic disorder, neuromuscular disease, alzheimer's disease, parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, muscle disorder, or immune related disorder; Pharmaceutical preparations for health care; Vaccines; Diagnostic reagents for medical use; Cultures of Microorganisms for medical purposes; Biotechnological preparations in the nature of enzymes for medical purposes; Stem cells for medical purposes; Enzymes for medical purposes; Nucleic acid sequences for medical and veterinary purposesACTIVE—
042Scientific research in the fields of biomedicine; Pharmaceutical drug development services; Research and development of technology for medicinal chemical manufacturing; scientific research in the nature of evaluating clinical trialsACTIVE—
044Medical and health assessment services relating to DNA, genetics and genetic testing; Genetic testing for medical treatment purposes; Provision of genetic testing for medical treatment purposes; Provision of Genetic information for medical treatment purposes; Providing gene therapy for medical treatment purposes; Genetic counseling for medical purposes; Medical diagnostic testing, monitoring and reporting services; DNA analysis for medical purposes; DNA screening for medical purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 6, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 6, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 21, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 21, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 1, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 11, 2024ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Apr 4, 2024ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Apr 1, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 18, 2024XAECEXAMINER'S AMENDMENT ENTERED—
Mar 18, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 18, 2024GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 18, 2024CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 18, 2024ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Mar 4, 2024OTHECASE RETURNED TO EXAMINATION—
Mar 4, 2024IUCNNOTICE OF ALLOWANCE CANCELLED—
Feb 6, 2024JURTJURISDICTION RESTORED TO EXAMINING ATTORNEY—
Feb 5, 2024PCBGPETITION TO DIRECTOR - CHANGE BASIS - GRANTED—
Feb 5, 2024APETASSIGNED TO PETITION STAFF—
Jan 31, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 30, 2024EX1GSOU EXTENSION 1 GRANTED—
Jan 30, 2024AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jan 12, 2024EXT1SOU EXTENSION 1 FILED—
Jan 12, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 8, 2024TPADTEAS PETITION TO AMEND BASIS RECEIVED—
Jul 18, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 23, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 23, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 3, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 20, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 8, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 7, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 7, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 13, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 13, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 13, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 13, 2023DOCKASSIGNED TO EXAMINER—
Jun 29, 2022ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
May 10, 2022AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
May 9, 2022PARITEAS VOLUNTARY AMENDMENT RECEIVED—
May 5, 2022AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
May 5, 2022ALIEASSIGNED TO LIE—
Apr 29, 2022PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Apr 18, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 15, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance